2017年9月
A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy
HEMATOLOGICAL ONCOLOGY
- 巻
- 35
- 号
- 3
- 開始ページ
- 288
- 終了ページ
- 295
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1002/hon.2285
- 出版者・発行元
- WILEY
We have reported the efficacy of the salvage chemotherapy P-IMVP16/CBDCA for patients with diffuse large B cell lymphoma (DLBCL) who had previously received CHOP before the availability of rituximab (R). Here, we confirmed the efficacy of R combined with P-IMVP16/CBDCA as a salvage chemotherapy for patients with DLBCL, who had previously received R-CHOP. We retrospectively analysed 59 patients with relapse or refractory DLBCL (38 male patients and 21 female patients) presenting between June 2004 and June 2013. The patients received R 375mg/m(2) on day 1, methylprednisolone 1000mg/body for 3days (from day 3 to day 5), ifosfamide 1000mg/m(2) for 5days (from day 3 to day 7), methotrexate 30mg/m(2) on day 5 and day 12, etoposide 80mg/m(2) for 3days (from day 3 to day 5), and carboplatin 300mg/m(2) on day 3 every 21days. Patients aged 70years or older were given 75% of the standard dose. The overall response rate (complete response+partial response) was 64.4%. The 2-year overall survival rate was 55.3%. The 2-year progression free survival rate was 34.7%. The 2-year overall survival rate was 61.5% for the relapse patients, and 15.6% for the refractory patients (p<0.0001). One patient died because of sepsis related to the treatment regimen. Non-hematological adverse effects were mild and tolerable. The R-P-IMVP-16/CBDCA regimen displayed a significant activity in relapsed DLBCL, with acceptable toxicity, and should be considered a candidate for salvage chemotherapy. Copyright (c) 2016 John Wiley & Sons, Ltd.
- リンク情報
-
- DOI
- https://doi.org/10.1002/hon.2285
- Web of Science
- https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000410668700003&DestApp=WOS_CPL
- URL
- http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84962488991&origin=inward
- ID情報
-
- DOI : 10.1002/hon.2285
- ISSN : 0278-0232
- eISSN : 1099-1069
- SCOPUS ID : 84962488991
- Web of Science ID : WOS:000410668700003